2- (4- (3- quinolin- 6- ylmethyl- 3H- (1,2,3)triazolo(4,5- b)pyrazin- 5- yl)pyrazol- 1- yl)ethanol

04/01/2012 - "Antitumor efficacy of PF-04217903 was dose-dependent and showed a strong correlation with inhibition of c-Met phosphorylation, downstream signaling, and tumor cell proliferation/survival. "
01/01/2021 - "Pretreatment studies were performed in the tumor bearing mice with the MET inhibitor PF04217903. "
04/01/2012 - "In human xenograft models that express relatively high levels of c-Met, complete inhibition of c-Met activity by PF-04217903 only led to partial tumor growth inhibition (38%-46%) in vivo. "
06/15/2013 - "Prevention of lymph node metastasis by PF-04217903 in this setting implicates c-Met signaling in tumor cell spread to lymph nodes."
04/01/2012 - "Furthermore, PF-04217903 strongly induced phospho-PDGFRβ (platelet-derived growth factor receptor) levels in U87MG xenograft tumors, indicating a possible oncogene switching mechanism in tumor cell signaling as a potential resistance mechanism that might compromise tumor responses to c-Met inhibitors. "

06/15/2013 - "c-Met blockade by the selective inhibitor, PF-04217903, significantly reduced metastasis to local lymph nodes. "
03/01/2012 - "However, invasion and metastasis were reduced by concurrent inhibition of c-Met by PF-04217903 or PF-02341066 (crizotinib). "

01/01/2017 - "Experimental mouse treated with PF-04217903 (c-Met antagonist) and in control group were induced to form intracranial aneurysms. "
03/01/2015 - "Intracranial aneurysms were induced in mice treated with PF-04217903 (a c-Met antagonist) or vehicle. "
01/01/2017 - "The intracranial aneurysm model was induced by surgery on adult c57/B16 mouse and grouping administration of c-Met antagonist PF-04217903 or its solvent DMSO for 3 weeks. "

01/01/2023 - "In total, 120 DEGs were discovered in a mouse model of doxorubicin-induced cardiotoxicity, and PF-04217903, propranolol, azithromycin, etc. were found to be potential drugs against this pathological condition. "

01/01/2012 - "We rendered a MET amplified gastric cancer cell line, GTL16, resistant to c-Met inhibition with prolonged exposure to a c-Met inhibitor, PF-04217903 (METi). "